DAWN - NASDAQ
Day One Biopharmaceuticals, Inc.
$21.53
+0.0000%Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotdawn
Cash at End of Period
Last Annual Value
197.08M
3-Year CAGR
32%
5-Year CAGR
35%
10-Year CAGR
22%
Day One Biopharmaceuticals, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 197.08M | -5.1% | -7.1% | N/A | |
 Geron Corporation NASDAQ:GERN | 79.44M | 3.7% | 17.7% | 20.0% | |
 Astria Therapeutics, Inc. NASDAQ:ATXS | 59.82M | -30.2% | -7.1% | 9.7% | |
 Tyra Biosciences, Inc. NASDAQ:TYRA | 78.39M | 10.6% | -23.7% | N/A | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 45.54M | -32.8% | 4.1% | N/A | |
 Arvinas, Inc. NASDAQ:ARVN | 142.90M | -23.3% | 4.8% | 39.6% | |
 Erasca, Inc. NASDAQ:ERAS | 74.21M | -7.4% | -27.1% | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 241.07M | -1.8% | -7.9% | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 112.82M | -8.7% | -9.3% | N/A | |
 Rezolute, Inc. NASDAQ:RZLT | 94.11M | 80.4% | 18.1% | 36.9% |
Day One Biopharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your DAWN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.